source
- FDA grants accelerated approval for Tzield to delay insulin loss in children with newly diagnosed Stage 3 type 1 diabetesThe U.S. Food and Drug Administration issued an accelerated approval on June 12, 2026 for Tzield (teplizumab) to slow the decline of insulin production in pediatric patients aged 8 to 17 who have r…
- Medicare to cover GLP-1 weight-loss drugs for seniors under temporary Trump-backed programStarting July 1, Medicare will make GLP-1 weight-loss drugs available to adults 65 and older at a cost of $50 per prescription through a new demonstration program. The initiative, called Bridge, i…STAT · 2mo agoRegulatoryNeutral